USPTO serial 79378921
BIOMEBANK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 13, 2026
- Examiner
- BURRUS, JESSICA E
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIOMEBANK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jocelyn C. Smith
Jocelyn C. Smith UB Greensfelder LLP65 E STATE ST, SUITE 1100COLUMBUS, OH 43215United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological agents, namely, bacterial fungicides, fungicides, weedkillers, herbicides, insecticides, parasiticides, and pesticides; biological control agents being pesticides; biological preparations for medical purposes, namely, the treatment of cancer; biological preparations for pharmaceutical purposes, namely, the treatment of cancer; biological preparations for use in cell cultures in biotechnology for medical purposes; biological preparations for use in cell cultures for medical purposes; biological products being reagents for medical use; biological substances being reagents for medical use; biological tissue cultures for medical purposes; biological reagants for use in biological processing for medical purposes; bacteriological culture mediums for medical purposes or veterinary purposes; bacteriological cultures for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic test reagants for medical use in detecting allergenic substances | ACTIVE | — |
| 042 | Biological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; bacteriological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biotechnology research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biotechnology testing of materials in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; advisory services relating to scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; technology advisory services related to biotechnological engineering research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biochemistry research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of biotechnology animal genetics research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; medical research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research for medical purposes in the field of cancerous diseases for the development, testing, and treatment of cultured microbial therapies; scientific research, namely, preparation of reports in the field of in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; Technical research, in the field of in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research, namely, conducting statistical scientific studies in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; providing information in the field of scientific and technological research and design services via a web site in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; provision of information relating to scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; provision of medical research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; rental of scientific research facilities in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; research and development of new products in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of bacteriology for the development, testing, and treatment of cultured microbial therapies; scientific research and development of new products in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of biology for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of genetics for the development, testing, and treatment of cultured microbial therapies; technological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; providing scientific information in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies. | ACTIVE | — |
| 044 | Medical advisory services, namely, advisory services relating to medical services for the testing and treatment of cultured microbial therapies; alternative medical services for the testing and treatment of cultured microbial therapies; charitable services, namely, providing medical services to underserved communities for the testing and treatment of cultured microbial therapies; medical services in the field of gastroenterology for the testing and treatment of cultured microbial therapies; medical diagnostic services in the nature of testing and analysis services for the testing and treatment of cultured microbial therapies; medical advisory services, namely, advisory services relating to medical problems for the testing and treatment of cultured microbial therapies. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by COST-BRY PTY LTD
- Other trademarks owned by COST-BRY PTY LTD
- Other trademarks owned by COST-BRY PTY LTD
- Other trademarks owned by COST-BRY PTY LTD
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BIOMEBANK
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 25, 2026 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Aug 20, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 5, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 5, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 5, 2026 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jun 1, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 13, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 2, 2026 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Jan 14, 2026 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Jan 13, 2026 | APET | ASSIGNED TO PETITION STAFF | — |
| Jan 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 18, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Nov 10, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Aug 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 7, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 10, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 10, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 4, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 1, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 6, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 6, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jul 28, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 6, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 6, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 5, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 5, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 17, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 19, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 15, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 14, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |